New combination therapy for PNH when current treatment isn't working
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new combination of two drugs (pozelimab and cemdisiran) for adults with PNH whose current treatment (eculizumab, ravulizumab, or crovalimab) isn't controlling their symptoms well. It aims to see if the combination reduces red blood cell breakdown and improves blood counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with paroxysmal nocturnal hemoglobinuria (PNH) through a blood test.
- You have been on eculizumab, ravulizumab, or crovalimab for at least 6 months.
- Your LDH levels have been high (above 1.5 times the normal limit) for the past 6 months, and your doctor thinks it's due to red blood cell breakdown.
- You are willing to get the meningococcal vaccine series (if not already up to date) and keep it current during the study.
- You have not had an organ transplant, bone marrow transplant, or other blood cell transplant.
- You do not have an active infection or have had one within the last 2 weeks before screening.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether long-term treatment with pozeli(z)umab plus cemdisiran is safe and works well in adults with paroxysmal nocturnal hemoglobinuria (PNH). It is mainly for people whose PNH does not respond to certain standard medicines or who have genetic changes that make them refractory.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
This trial tests a new drug, HS-10542, for people with PNH who are already on a C5 inhibitor like eculizumab or covalizumab but still have low hemoglobin or need transfusions. It aims to see if this additional treatment can improve blood counts and reduce transfusion needs.
This study tests a new pill (FXS6837) against a standard treatment (eculizumab) for people with PNH. The goal is to see if the pill is safe and effective in improving anemia and reducing the need for transfusions.
This trial tests a new investigational drug called NM8074 for people with PNH whose disease is not well controlled on Soliris. It aims to see if this new treatment can improve their anemia and reduce the need for blood transfusions.
This trial is testing an experimental pill called NTQ5082 for people with PNH who haven't been treated with complement inhibitors before. The goal is to see if it can improve anemia and control PNH symptoms like fatigue and blood clots.
Hear when a new Paroxysmal Nocturnal Hemoglobinuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.